Qiagen (QGEN) fully acquires NeuMoDx Molecular

Go back to Qiagen (QGEN) fully acquires NeuMoDx Molecular

QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

September 17, 2020 4:05 PM EDT

Transaction strengthens QIAGENs leadership position in automated molecular testing QIAGEN acquires remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million Medium- and high-throughput NeuMoDx automation solutions based on PCR testing technology to now be integrated into QIAGENs portfolio on a global basis Menu of test solutions for infectious diseases which already includes COVID-19 to be expanded, especially in the U.S.

HILDEN, Germany & ANN ARBOR, Mich.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)... More